uniQure N.V. - Ordinary Shares (QURE)

CSL and uniQure's Hemgenix shows sustained efficacy in hemophilia B, reducing bleeding rates by 90% and eliminating prophylaxis need for most patients at year four.

The company is testing a gene therapy for Huntington's disease and could soon seek an accelerated approval.

uniQure stock surges after FDA agrees on an accelerated approval pathway for its Huntington's disease treatment, AMT-130.

QURE stock results show that uniQure beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

UniQure N.V. (NASDAQ: QURE) shares are skyrocketing Wednesday following the release of promising interim data from its Phase I/II clinical trials of AMT-130, a gene therapy targeting Huntington's disease.

UniQure shares are trading higher Tuesday after the company announced updated interim data from its ongoing U.S. and European Phase I/II clinical trials of AMT-130 for the treatment of Huntington's disease. Here's a look at the details:

Mullen stock is down on Tuesday even as MULN shareholders learn of a new EV order for subsidiary Bollinger Motors from Spencer Manufacturing.

UniQure stock is up on Tuesday as QURE investors react to positive clinical trial data for its Huntington’s Disease treatment candidate.

QURE stock results show that uniQure missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

Pfizer won FDA approval for a new hemophilia B gene therapy, a rival to Hemgenix from CSL and Uniqure.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results.